Biotechnology shares and sector-related alternate traded funds stood out Friday after regulators breathed new life into Biogen (NasdaqGS: BIIB) and its associate Eisai Co. (ESALY) on a brand new Alzheimer’s drug candidate. Among the many high performing non-leveraged ETFs of Friday, the VanEck Vectors Biotech ETF (BBH) rose 2.1% and iShares Nasdaq Biotechnology ETF (IBB) gained 0.6%. […] Learn extra at ETFtrends.com.
www.nasdaq.com
Biotechnology ETFs Soar on Biogen’s New Alzheimer’s Drug
